US · Healthcare · Biotechnology
EPS came in at -0.86 against a street estimate of -0.70 — a miss of 22.9%.
Analysts rate Ginkgo Bioworks Holdings a sell (0 buy, 1 hold, 2 sell out of 3) with an average price target of $8.00.
| Fund | Stake |
|---|---|
| BlackRock Inc | 6.36% |
| Viking Global Investors LP | 5.31% |
| Erste Asset Management GmbH | 3.77% |
| Baillie Gifford & Co Limited. | 3.55% |
| Vanguard Capital Management, LLC | 3.10% |
| Anchorage Advisors, LLC | 2.59% |
| Legal & General Group PLC | 2.48% |
| State Street Corp | 2.19% |
| Document | Date |
|---|---|
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 revenue was $27.711 million, compared with $29.380 million in Q3 2025, a decrease of 6%. Revenue increased from $20 millio | 2026-11-05 |
| Reg FD disclosure · Q4 2026 HEADLINE NUMBERS • Ginkgo Bioworks Holdings, Inc. filed a Form 8-K dated October 29, 2026. • The filing does not provide third-quarter financial res | 2026-10-29 |
| Quarterly report · Q2 2026 HEADLINE NUMBERS • Second-quarter 2026 revenue was $20,156, down from $39,134 in the second quarter of 2025. • Six-month revenue was $39,630, down f | 2026-08-06 |
| Results announced · Q3 2026 HEADLINE NUMBERS • Q2 2026 revenue was $20 million, down 48% from $39 million in Q2 2025, mainly because of ongoing program rationalization related t | 2026-08-05 |
| Reg FD disclosure · Q3 2026 HEADLINE NUMBERS • Ginkgo Bioworks Holdings, Inc. filed a Form 8-K dated July 30, 2026. • The filing does not provide second-quarter financial resul | 2026-07-30 |
| Shareholder vote results · Q2 2026 HEADLINE NUMBERS • Ginkgo Bioworks held its 2026 annual shareholder meeting on June 11, 2026. • 39,536,848 Class A shares and 8,405,525 Class B shar | 2026-06-12 |
| Quarterly report · Q1 2026 HEADLINE NUMBERS • Q1 2026 revenue was $19.474 million, down from $38.230 million in Q1 2025. • Net loss was $82.587 million, compared with $90.957 | 2026-05-07 |
| Results announced · Q2 2026 HEADLINE NUMBERS • Q1 2026 revenue was $19 million, down 49% from $38 million in Q1 2025. • Excluding $7 million of non-cash deferred-revenue recogn | 2026-05-07 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Ginkgo Bioworks Holdings — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.